NCT04150328

Lenalidomide Monotherapy in R/R DLBCL

An Observational Retrospective Cohort Study of Lenalidomide Monotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) to Generate a Historical Control for Clinical Trial MOR208C203 (RE-MIND)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 490 (actual)
• Sponsor: MorphoSys AG · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This observational study is designed to characterise the effectiveness of lenalidomide monotherapy in the treatment of R/R DLBCL and to compare the results with the efficacy outcomes of a tafasitamab-lenalidomide combination therapy in the clinical trial MOR208C203 (L-MIND)

Detailed description

Tafasitamab (MOR00208) is currently in development for the treatment of R/R DLBCL. An ongoing, single-arm, phase II, open label, multicenter study (MOR208C203) is evaluating the efficacy and safety of tafasitamab combined with lenalidomide in patients with R/R DLBCL. In order to establish a lenalidomide monotherapy as a control cohort, this observational study aims to collect retrospective lenalidomide monotherapy data from real-world-evidence and to compare it with the tafasitamab-lenalidomide combination therapy.

Conditions

• Diffuse Large B Cell Lymphoma

Timeline

• Start date: 2019-04-12
• Primary completion: 2019-08-25
• Completion: 2020-08-25
• First posted: 2019-11-04
• Last updated: 2022-08-24

Locations

57 sites across 4 countries: United States, France, Italy, Spain